Skip to main content
SpringerLink
Log in

Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel

A Systematic Review

  • Systematic Review
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: There is considerable debate regarding the negative impact of concomitant proton pump inhibitor (PPI) therapy on the antiplatelet efficacy of clopidogrel.

Aim: The aim of this study was to perform a systematic review of studies that have evaluated the platelet function of patients receiving clopidogrel alone compared with those receiving both clopidogrel and PPIs.

Methods: We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register in February 2011 for randomized and non-randomized studies that reported platelet function results in patients taking clopidogrel, with or without PPIs.

Results: Our review included 19 studies (13 trials and 6 observational studies) involving 4693 patients. There was considerable heterogeneity in the study designs, patient characteristics, laboratory tests of platelet function, and drug exposure (dose and duration of PPI and clopidogrel). There was some evidence against omeprazole, with five of nine studies demonstrating a significant interaction with clopidogrel. The available platelet function data on esomeprazole (six studies) or pantoprazole (six studies) did not demonstrate a significant interaction. Of the six studies that statistically analysed platelet function data with omeprazole compared with pantoprazole, three showed a significantly greater interaction between omeprazole and clopidogrel, whereas three studies with limited sample sizes were unable to find a significant difference in the effects of omeprazole and pantoprazole.

Conclusion: Platelet function studies do not demonstrate a clear or consistent interaction between clopidogrel and PPIs. These studies are difficult to interpret given the lack of information on drug exposure (dose and duration), variation in laboratory methodology and lack of genetic information. Consequently, platelet function data are of uncertain clinical relevance in determining the risk of an adverse cardiovascular interaction between PPIs and clopidogrel. Clinicians should continue to clinically assess the gastrointestinal risk of the patients and make their prescribing decision for PPIs based on any anticipated benefits in reducing risk of peptic ulcers and gastrointestinal haemorrhage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction. Am J Gastroenterol 2010; 105: 34–41

    Article  PubMed  CAS  Google Scholar 

  2. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54: 1149–53

    Article  PubMed  CAS  Google Scholar 

  3. Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256–60

    Article  PubMed  CAS  Google Scholar 

  4. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989–97

    Article  PubMed  Google Scholar 

  5. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909–17

    Article  PubMed  CAS  Google Scholar 

  6. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937–44

    Article  PubMed  CAS  Google Scholar 

  7. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713–8

    PubMed  Google Scholar 

  8. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31: 810–23

    PubMed  CAS  Google Scholar 

  9. US Food and Drug Adminstration. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm [Accessed 2011 Jun 27]

  10. Cai J, Wu Q, Fan L, et al. Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation [in Chinese]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2010; 26: 266–9

    PubMed  CAS  Google Scholar 

  11. Guo Q, Jin W. Effects of esomeprazole and omeprazole on clopidogrel platelet inhibition following cardiac stent implantation [in Chinese]. J Clin Rehab Tissue Engineering Res 2009; 13: 10283–6

    CAS  Google Scholar 

  12. Hsu P, Lai K, Liu C. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011; 140: 791–8

    Article  PubMed  CAS  Google Scholar 

  13. Siriswangvat S, Sansanayudh N, Nathisuwan S, et al. Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J 2010; 74: 2187–92

    Article  PubMed  CAS  Google Scholar 

  14. Zhang R, Ran HH, Zhu HL, et al. Differential effects of esomeprazole on the antiplatelet activity of clopidogrel in healthy individuals and patients after coronary stent implantation. J Int Med Res 2010; 38: 1617–25

    Article  PubMed  CAS  Google Scholar 

  15. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89: 65–74

    Article  PubMed  CAS  Google Scholar 

  16. Fontes-Carvalho R, Albuquerque A, Araujo C, et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur J Gastroenterol Hepatol 2011; 23: 396–404

    Article  PubMed  CAS  Google Scholar 

  17. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010; 70: 383–92

    Article  PubMed  CAS  Google Scholar 

  18. Yun KH, Rhee SJ, Park HY, et al. Effects of omeprazole on the antiplatelet activity of clopidogrel. Int Heart J 2010; 51: 13–6

    Article  PubMed  CAS  Google Scholar 

  19. Gremmel T, Steiner S, Seidinger D, et al. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol 2010; 56: 532–9

    Article  PubMed  CAS  Google Scholar 

  20. Neubauer H, Engelhardt A, Kruger JC, et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel: a whole blood aggregometry study after coronary stenting. J Cardiovasc Pharmacol 2010; 56: 91–7

    Article  PubMed  CAS  Google Scholar 

  21. Price MJ, Nayak KR, Barker CM, et al. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 103: 1339–43

    Article  PubMed  CAS  Google Scholar 

  22. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714–9

    PubMed  CAS  Google Scholar 

  23. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-5

    Article  PubMed  Google Scholar 

  24. Zuern CS, Geisler T, Lutilsky N, et al. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res 2010; 125: e51–4

    Article  PubMed  Google Scholar 

  25. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304: 1821–30

    Article  PubMed  CAS  Google Scholar 

  26. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110–6

    Article  PubMed  CAS  Google Scholar 

  27. Dawson J, Quinn T, Rafferty M, et al. Aspirin resistance and compliance with therapy. Cardiovasc Ther 2010; 29: 301–7

    Article  PubMed  Google Scholar 

  28. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097–105

    Article  PubMed  CAS  Google Scholar 

  29. Kwok CS, Nijjar RS, Loke YK. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf 2011; 34: 47–57

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Y.K. Loke and C.S. Kwok conceptualized the review, developed the protocol, abstracted and analysed data and wrote the manuscript. Y.K. Loke will act as the guarantor for the study.

The authors have no competing interests to declare. No funding was received.

Author information

Authors and Affiliations

  1. School of Medicine, Health Policy and Practice, University of East Anglia, Earlham Road, Norwich, NR4 7TJ, UK

    Chun Shing Kwok &  Yoon Kong Loke

Authors
  1. Chun Shing Kwok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoon Kong Loke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoon Kong Loke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwok, C.S., Loke, Y.K. Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel. Drug Saf 35, 127–139 (2012). https://doi.org/10.2165/11594900-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11594900-000000000-00000

Keywords

Search

Navigation